Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

President and CEO

Chief Development Officer

See Remarks

Chief Financial Officer

Chief Commercial Officer

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	bought	Premium	Premium	Premium	-
2024-04-04	Premium	bought	Premium	Premium	Premium	-
2024-04-03	Premium	bought	Premium	Premium	Premium	-
2024-04-02	Premium	bought	Premium	Premium	Premium	-
2024-04-01	Premium	bought	Premium	Premium	Premium	-
2024-03-12	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-12	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-03-11	Premium	sold	Premium	Premium	Premium	Chief Development Officer
2024-03-11	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-11	Premium	sold	Premium	Premium	Premium	President and CEO
2023-10-18	Premium	sold	Premium	Premium	Premium	-
2023-10-16	Premium	sold	Premium	Premium	Premium	-
2023-09-07	Premium	acquired	Premium	Premium	Premium	-
2023-09-07	Premium	acquired	Premium	Premium	Premium	President and CEO
2023-09-07	Premium	sold (taxes)	Premium	Premium	Premium	President and CEO
2023-08-22	Premium	acquired	Premium	Premium	Premium	-
2023-06-27	Premium	acquired	Premium	Premium	Premium	-
2023-02-28	Premium	acquired	Premium	Premium	Premium	President and CEO
2022-08-10	Premium	bought	Premium	Premium	Premium	-
2022-08-09	Premium	bought	Premium	Premium	Premium	-
2022-08-08	Premium	bought	Premium	Premium	Premium	-
2022-08-05	Premium	bought	Premium	Premium	Premium	-
2022-08-04	Premium	bought	Premium	Premium	Premium	-

ALDX - Aldeyra Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ALDX